Fortress Biotech (FBIOP) Metrics: History & Chart

Fortress Biotech, Inc.(FBIOP)

Biotechnology · Bay Harbor Islands, FL

$18.10+1.24 (+7.35%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Fortress Biotech, Inc.

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Bay Harbor Islands, FL

78 employees

www.fortressbiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lindsay A. Rosenwald

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	+9.56%
30D Total Return	-3.47%
YTD Total Return	+90.73%
1Y Total Return	+145.26%
3Y Total Return	+81.92%
5Y Total Return	+0.25%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+90.73%
2025	+42.71%
2024	-39.72%
2023	-21.86%
2022	-23.74%
2021	+46.67%
2020

CAGR TTM	+144.21%
CAGR 3Y	+22.07%
CAGR 5Y	+0.05%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	6.75
PE Ratio Avg TTM	6.27
PE Ratio Avg 3Y	6.27
Current VS TTM Avg	+7.73%
Current VS 3Y Avg	+7.73%
Current VS 5Y Avg	+7.73%

All Metrics

FBIOP Valuation Metrics

FBIOP Stock Price Metrics

FBIOP Dividend Metrics

FBIOP Growth Rate Metrics

FBIOP Discounted Cash Flow Metrics

FBIOP Returns By Period

FBIOP Yearly Returns

FBIOP Average Annual Returns By Period (CAGR)

FBIOP Revenue Metrics

FBIOP PE Ratio Metrics

FBIOP PS Ratio Metrics

FBIOP PB Ratio Metrics

FBIOP Price to Free Cash Flow Ratio Metrics

FBIOP Debt to Equity Ratio Metrics

FBIOP PEG Ratio Metrics

FBIOP FCF Yield

FBIOP Earnings Yield

FBIOP EBITDA Yield

FBIOP OCF Yield

FBIOP EV/EBIT Ratio Metrics

FBIOP EV/EBITDA Ratio Metrics

FBIOP EV/Assets Ratio Metrics

FBIOP EV/Sales Ratio Metrics

FBIOP Current Ratio Metrics

FBIOP Quick Ratio Metrics

FBIOP ROIC Metrics

FBIOP Return on Assets Metrics

FBIOP Return on Equity Metrics

FBIOP Net Profit Margin Metrics

FBIOP Gross Profit Margin Metrics

FBIOP Tax Rate Metrics

PS Ratio	9.78
PS Ratio Avg TTM	7.67
PS Ratio Avg 3Y	3.62
Current VS TTM Avg	+27.58%
Current VS 3Y Avg	+169.83%
Current VS 5Y Avg	+371.55%

PB Ratio	4.08
PB Ratio Avg TTM	5.87
PB Ratio Avg 3Y	6.04
Current VS TTM Avg	-30.50%
Current VS 3Y Avg	-32.46%
Current VS 5Y Avg	-11.20%

PFCF Ratio	5.32
PFCF Ratio Avg TTM	4.90
PFCF Ratio Avg 3Y	4.90
Current VS TTM Avg	+8.47%
Current VS 3Y Avg	+8.47%
Current VS 5Y Avg	+8.47%

Debt/Equity Ratio	0.39
Debt/Equity Ratio Avg TTM	1.00
Debt/Equity Ratio Avg 3Y	2.82
Current VS TTM Avg	-60.64%
Current VS 3Y Avg	-85.99%
Current VS 5Y Avg	-83.46%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	18.78%
FCF Yield Avg TTM	20.46%
FCF Yield Avg 3Y	20.46%
Current VS TTM Avg	-8.23%
Current VS 3Y Avg	-8.23%
Current VS 5Y Avg	-8.23%

Earnings Yield	14.82%
Earnings Yield Avg TTM	15.97%
Earnings Yield Avg 3Y	15.97%
Current VS TTM Avg	-7.21%
Current VS 3Y Avg	-7.21%
Current VS 5Y Avg	-7.21%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	1.70
Ev/Assets Ratio Avg TTM	1.79
Ev/Assets Ratio Avg 3Y	1.24
Current VS TTM Avg	-4.77%
Current VS 3Y Avg	+36.71%
Current VS 5Y Avg	+67.70%

Ev/Sales Ratio	7.86
Ev/Sales Ratio Avg TTM	6.51
Ev/Sales Ratio Avg 3Y	3.60
Current VS TTM Avg	+20.77%
Current VS 3Y Avg	+118.46%
Current VS 5Y Avg	+239.88%

Current Ratio	3.96
Current Ratio Avg TTM	2.68
Current Ratio Avg 3Y	1.65
Current VS TTM Avg	+47.52%
Current VS 3Y Avg	+140.55%
Current VS 5Y Avg	+78.61%

Quick Ratio	3.83
Quick Ratio Avg TTM	2.51
Quick Ratio Avg 3Y	1.49
Current VS TTM Avg	+52.35%
Current VS 3Y Avg	+156.48%
Current VS 5Y Avg	+84.80%

ROIC	(10.85%)
ROIC Avg 3Y	(131.92%)
ROIC Avg 5Y	(102.76%)
Current VS 3Y Avg	+91.78%
Current VS 5Y Avg	+89.45%
Current VS 10Y Avg	+84.80%

ROA	35.31%
ROA Avg TTM	8.31%
ROA Avg 3Y	(4.13%)
Current VS TTM Avg	+324.73%
Current VS 3Y Avg	+954.33%
Current VS 5Y Avg	+725.83%

ROE	68.12%
ROE Avg TTM	26.83%
ROE Avg 3Y	(169.45%)
Current VS TTM Avg	+153.87%
Current VS 3Y Avg	+140.20%
Current VS 5Y Avg	+145.80%

Net Profit Margin	163.32%
Net Profit Margin Avg TTM	157.75%
Net Profit Margin Avg 3Y	(42.34%)
Current VS TTM Avg	+3.53%
Current VS 3Y Avg	+485.75%
Current VS 5Y Avg	+324.98%

Gross Profit Margin	62.53%
Gross Pft Margin Avg TTM	63.93%
Gross Pft Margin Avg 3Y	63.49%
Current VS TTM Avg	-2.19%
Current VS 3Y Avg	-1.51%
Current VS 5Y Avg	+4.90%

Tax Rate	33.11%
Tax Rate Avg 3Y	12.34%
Tax Rate Avg 5Y	12.34%
Current VS 3Y Avg	+168.39%
Current VS 5Y Avg	+168.39%
Current VS 10Y Avg	+168.39%